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ABSTRACT
TNF-α antagonists are used to treat various rheumatic diseases including sarcoidosis. However, there have been increasing reports of 
sarcoidosis in relation to treatment using these drugs. The pathogenesis of this reaction remains unknown.
This is a report of a clinical case of sarcoidosis in Behçet's disease (DB) with mucocutaneous and intestinal involvement in treatment using 
adalimumab, with improvement after anti-TNF suspension and corticosteroid therapy.
LEARNING POINTS
•	 This	clinical	case	demonstrates	the	efficacy	of	the	anti-TNFa	adalimumab	in	the	treatment	of	Behçet	with	intestinal	manifestations	and	
not responsive to other therapeutics.
•	 To	our	knowledge	it	is	the	first	time	it	is	described	a	case	of	sarcoid	reaction	in	a	patient	with	Behçet	treated	with	adalimumab.
• It shows how two complications of the use of immunosuppressants (sarcoid reaction and Legionella pneumophila pneumonia) in the same 
patient	can	difficult	the	correct	diagnosis	because	of	the	many	and	overlapping	clinical	manifestations.
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INTRODUCTION
Tumor	necrosis	factor	(TNF)	is	a	proinflammatory	cytokine	produced	by	activated	macrophages,	CD4	+	lymphocytes,	NK	cells,	and	other	
factors.	Anti-TNF	agents	are	used	in	the	treatment	of	various	inflammatory	diseases	such	as	rheumatoid	arthritis,	psoriatic	arthritis,	and	
ankylosing spondylitis[1].
The use of anti-TNF in patients with Behçet's disease has been described in several patients with manifestations refractory to conventional 
medication, resulting in impressive remissions[1,2].
The most commonly used TNF-α	antagonists	include	infliximab	and	adalimumab	(monoclonal	antibodies	against	TNF-α) and etanercept (a 
fusion protein that binds TNF-α mimicking its soluble receptor). These agents have also proved to be effective in the treating sarcoidosis 
and	other	inflammatory	conditions.	However,	sarcoidosis-like	paradoxical	reactions	have	been	reported	in	approximately	1/2800	patients	
treated	with	anti-TNF	in	inflammatory	arthropathies[3].
A case of Behçet's disease treated using adalimumab is reported in which the patient was diagnosed with sarcoidosis 6 months after 
starting treatment, and also with Legionella pneumophila pneumonia. The patient improved after anti-TNF suspension and introduction of 
corticosteroids.
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2017_000576 European Journal of Case Reports in Internal Medicine © EFIM 2017
CASE REPORT
A	 47-year-old	man	with	 a	 17-year	 history	 of	 Behçet's	 disease	with	mucocutaneous	 and	 intestinal	 involvement	 presenting	 incomplete	
response to colchicine, corticosteroids, azathioprine, and sulfasalazine.
Initially medicated with colchicine and corticosteroids without complete resolution of complaints and additionally medicated with 
thalidomide with a total resolution of the symptomatology that, unfortunately, had to be suspended due to the side effect of sensitive 
polyneuropathy of the lower limbs. Corticosteroid dosage was escalated and azathioprine was introduced but without complete control of 
the complaints – the patient maintained oral and genital ulcers as well as asthenia. Sulfasalazine was also introduced because of intestinal 
manifestations such as abdominal pain, diarrhea, and hematochezia but without satisfactory resolution of the complaints.
Faced	with	 this	 resistance,	 the	patient	was	 treated	with	adalimumab	resulting	 in	a	 rapid	and	complete	 resolution	of	 the	symptoms.	Six	
months after initiation of treatment and about three days after the administration of another dose of adalimumab, the patient started to 
complain	of	fever	with	night	and	evening	predominance	associated	with	flank,	chest,	and	retrosternal	myalgias	and	inflammatory	arthralgia	
of the shoulders, elbows, knees, and metacarpophalangea joints. He also reported dizziness, headache, and mechanical neck pain. He had 
nausea without vomiting.
Physical	examination	revealed	oropharynx	without	thrush	or	ulcers.	No	cervical	or	axillary	adenopathies	on	palpation.	No	signs	of	arthritis.	
Lower	limbs	with	slightly	swollen	knees.	No	alterations	in	ophthalmologic	or	neurological	exams	and	in	cardiopulmonary	evaluation.
Blood	 test	 results:	Creatinine	0.74	mg/dL,	 Sodium	142	mmol/L,	Potassium	4.0	mmol/L,	CK	29	U/L,	PCR	8.74	mg/dL	Leukocytes	7,200;	
Neutrophils	61.1%;	Lymphocytes	22.0%;	Hemoglobin	14.2	g/dL,	VGM	91.3	fL,	Platelets	270,000;	SR	32	mm/h.
Chest X-ray: perihilar reinforcement.
Serologies	 were	 performed	 for	 Cytomegalovirus,	 Epstein-Barr	 Virus,	 Herpes	 simplex	 1	 and	 2,	 Chlamydia trachomatis, Coxiella burnetii, 
Mycoplasma pneumoniae, Clamydophila pneumoniae	 which	 were	 negative.	Mantoux	 test	 and	 IGRA	were	 also	 negative.	 Bronchoalveolar	
lavage,	bacteriological	examination,	and	mycobacterial	tuberculosis	detection	by	polymerase	chain	reaction	and	cultures	were	negative.	
Negative hemocultures.
Therapy	with	adalimumab	was	suspended	and	empirical	medicated	with	ceftriaxone	and	azithromycin	started	with	initial	improvement	of	
complaints.
About 2-3 days after the end of the antibiotic therapy, the patient started complaining of a continuous right chest pain, grade 6/10, which 
aggravated with mobilization and with right lateral decubitus position. He reported dry cough and night sweats, without fever. Appearance 
of erythema nodosum in both lower limbs.
Chest	radiography	revealed	bronchopneumonia	of	the	right	upper	lobe.	Analytically	with	PCR	38.5	mg/dL,	SR	47mm/hr,	and	increased	anti-
Legionella pneumophila IgM antibody titer from 1/320 to 1/1000.
Because no imaging improvement occurred, a high-resolution chest CT was performed that demonstrated nodulation reaching the right 
upper lobe, middle lobe, and lower lobes. Central permeable tracheobronchial tree. Multiple mediastinal and hilar adenomegalies reaching 
about	15	mm	short	axis.	There	was	a	small	volume	of	bilateral	pleural	effusion.
Legionella pneumonia was assumed and was treated with clarithromycin for 10 days. There was improvement in complaints, only right chest 
pain maintaining.
Thoracic CT was repeated one month later, which revealed a reduction in adenomegaly. Micronodulation was dispersed in both lungs. 
Analytically,	 it	 had	 ECA	 132	 U/L	 (8-52	 U/L).	 A	 mediastinal	 ganglion	 biopsy	 was	 performed	 that	 revealed	 confluent,	 non-necrotizing	
epithelioid granulomas and multinucleated Langhans and Touton giant cells, suggesting the diagnosis of sarcoidosis.
He	was	medicated	with	methylprednisolone	40mg	for	6	months.	CT	imaging	showed	complete	resolution	of	nodular	lesions	and	adenopathies.
DISCUSSION
A TNF-α induces macrophage differentiation of monocytes, essential for the induction and maintenance of granuloma integrity. It also 
plays an important role in host defense against infectious agents, especially in those with intracellular multiplication such as Legionella 
pneumophila. Cases of L. pneumophila pneumonia appear to be increasing in patients treated with TNF antagonists[4].
Pulmonary legionellosis may present as Legionnaires' disease, the most severe form, or as Pontiac Fever, the most moderate form, with fever 
and myalgias.
The patient presented in this article appears to have initially presented a more moderate form of the disease with fever and myalgias, and 
then subsequently progressed to pneumonia.
In this case, in spite of the directed treatment, the patient maintained right chest pain and pulmonary parenchymal alterations, with scattered 
micronodulations shown in imaging reevaluation. Sarcoidosis was evidenced by lymph node biopsy.
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It	was	difficult	to	distinguish	the	symptoms	caused	by	sarcoidosis	from	the	symptoms	caused	by	L. pneumophila pneumonia since some are 
overlapping.
Reports of the association of Behçet's disease with sarcoidosis are rare[6,7]. However, there are a growing number of reports in the literature 
of sarcoidosis related to treatment with TNF antagonists[3,8,9]. The incidence of this adverse effect is estimated at 1/2800. The majority of the 
fewer	than	40	cases	reported	to	date	have	involved	etanercept	therapy.	However,	all	three	agents	have	been	implicated[9]. The pathogenic 
mechanisms	involved	are	unknown	and	it	is	considered	to	be	a	paradoxical	effect,	taking	into	account	the	mode	of	action	of	these	agents	
since TNFα blockade suppresses granuloma formation.
It is thought that the phenomenon is independent of the underlying disease and has been reported in patients with rheumatoid arthritis, 
psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile rheumatoid arthritis, and polymyalgia rheumatic[8]. The duration of 
treatment	before	the	diagnosis	of	sarcoidosis	ranged	from	one	month	to	five	years.	Pulmonary,	ganglion,	cutaneous,	ocular,	hepatic,	parotid,	
and central nervous system involvement have all been reported.
In summary, the authors describe the occurrence of sarcoidosis in a subject with Behçet's disease which, due to the characteristics and 
temporal relationship, appears to be a direct consequence of the biologic treatment with adalimumab. 
As described in the literature reviewed, the resolution of granulomas generally occurs one year after drug withdrawal. In some cases the 
treatment also involved the introduction of corticosteroids as was the case for the patient presented in this article. It is also reported that 
substitution by other anti-TNF resulted in resolution of the condition[8-10].
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